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Abstract Methadone and buprenorphine are used in
maintenance therapy for heroin addicts. In this study, we
compared their effects on adenylate cyclase (AC) activity
in human embryonic kidney (HEK) 293 cells stably over-
expressing human l-opioid receptor (MOR) and nocicep-
tin/opioid receptor-like 1 receptor (ORL1) simultaneously.
After acute exposure, methadone inhibited AC activity;
however, buprenorphine induced compromised AC inhi-
bition. When naloxone was introduced after 30 min incu-
bation with methadone, the AC activity was enhanced. This
was not observed in the case of buprenorphine. Enhance-
ment of the AC activity was more signiﬁcant when the
incubation lasted for 4 h, and prolonged exposure to
buprenorphine elevated the AC activity as well. The
removal of methadone and buprenorphine by washing also
obtained similar AC superactivation as that revealed by
naloxone challenge. The study demonstrated that metha-
done and buprenorphine exert initially different yet even-
tually convergent adaptive changes of AC activity in cells
coexpressing human MOR and ORL1 receptors.
Keywords Opioid receptor  Adenylate cyclase activity 
Morphine  Methadone  Buprenorphine  Naloxone
Introduction
Three conventional opioid receptors—l (MOR), d (DOR),
and j (KOR)—have been characterized based on their
pharmacological, anatomical, and molecular properties
[1–3].Anon-opioidbranchofopioidreceptorshasalsobeen
identiﬁedandnamedasopioidreceptor-likeorphanreceptor
(ORL1) [4]. This receptor family was renamed after identi-
ﬁcation of its endogenous peptidergic agonist, nociceptin or
orphanin FQ, as the nociceptin/orphanin FQ peptide (NOP)
receptor; it displays pharmacology distinct from those of
conventional opioid receptors [5, 6]. Activation of l-, d-,
j- or ORL1 receptor produces common cellular actions by
regulating the same secondary messengers, including inhi-
bition of adenylate cyclase (AC) activity [7, 8] and N-type
[9] and L-type Ca
2? channels [10]. Activation of opioid
receptors also increases phospholipase C activity, causes a
transient increase in intracellular Ca
2? [11], and activates
inwardlyrectifying K
?channels[12] and mitogen-activated
protein kinases (MAPK) [13].
Methadone and buprenorphine are currently used in
maintenance treatment programs for heroin addicts [14, 15].
Methadone is an orally available synthetic opioid function-
ing as a full agonist of MOR. First tested as a treatment for
heroin addicts in early 1964 at The Rockefeller University,
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heroin through the mechanism of opioid cross-tolerance
[14]. Buprenorphine, a derivative of thebaine, differs from
standard opioid agonists in two aspects. The ﬁrst is the slow
receptor dissociation kinetics featured with the biphasic
(‘‘bell’’- or ‘‘inverted U’’-shaped) dose–response relation
[16,17].Thesecondisthatbuprenorphinehasaceilingeffect
on respiratory depression in humans, suggesting a greater
safety margin of buprenorphine relative to other clinical
opioids [18]. Methadone is a long-acting MOR agonist with
pharmacological properties qualitatively similar to those of
morphine, whereas buprenorphine is a MOR partial agonist
and a potent j-opioid receptor antagonist [19] as well as an
ORL1 agonist [16, 20].
Adaptive changes in neurons underlie altered behaviors
associated with opioid dependence and withdrawal syn-
drome [21]. Adaptations affect neuronal excitability, syn-
aptic transmission, transcription factors, and MAPK [22].
Prolonged exposure of NG108-15 neuroblastoma x glioma
hybrid cells (expressing mainly d-opioid receptors) to
morphine leads to increased AC activity [23], suggesting
this phenomenon may underlie the withdrawal state.
Withdrawal of the agonist by washing (natural withdrawal)
or by adding the antagonist naloxone (precipitated with-
drawal), which relieves the inhibition of AC exerted by the
agonist, revealed the phenomenon of AC superactivation or
overshoot. Such regulation of AC could be a general means
of cellular adaption to the alteration of opioid receptors
[24, 25].
In several subpopulations of CNS neurons involved in
pain regulation, MOR and ORL1 are coexpressed [26,
27]. Furthermore, heterodimerization of MOR and ORL1
impairs the potency of MOR agonist [28] and attenuates
ORL1-mediated inhibition of N-type channels [29].
Interestingly, mice lacking the ORL1 gene partially
lose tolerance liability to morphine analgesia [30] and
show marked attenuation of morphine-induced physical
dependence, manifested as naloxone-precipitated with-
drawal symptoms after repeated morphine treatments [31].
Hence, coexpressed MOR?ORL1 may reﬂect the native
opioid receptors in some CNS regions and could provide
the insight on the development of dependence on opioid
drugs.
The human embryonic kidney (HEK) 293 cell line is a
widely-distributed mammalian cell expression system and
shares similar protein expression proﬁles with human
neuronal cells [32]. In this study, we have established an in
vitro cell model overexpressing human MOR and ORL1
individually or simultaneously in human embryonic kidney
(HEK) 293 cells. Alterations of AC activity after acute
or prolonged exposure to methadone and buprenorphine
were compared in this model. Naloxone was utilized to
demonstrate the speciﬁcity of the drugs and elicit the
precipitated withdrawal. Effects of morphine and Ro
64-6198 were also examined as positive control for MOR
and ORL1, respectively.
Experimental Procedure
Molecular Cloning of Human l-Opioid and ORL1
Receptors
The full-length cDNA clones encoding the human MOR
(CloneID30915262)andORL1receptor(CloneID5164017)
were purchased from Open Biosystems (Huntsville, AL,
USA). HA epitope (YPYDVPDYA) was added to the
N-terminus of MOR with the aid of PCR ampliﬁcation. Sub-
sequently, cDNA of HA-tagged MOR was subcloned into a
mammalian expression vector, pcDNA4/V5-His C (Invitro-
gen,Carlsbad,CA,USA),whichisa zeocin-selectable vector
[28]. The cDNA encoding ORL1 was subcloned into a
mammalian expression vector, pCMV-Tag3 (Stratagene, La
Jolla, CA, USA), which is a geneticin-selectable vector pro-
viding a myc tag (EQKLISEEDL) to the N-terminus. All
sequences were veriﬁed by DNA sequence analysis.
Stable Expression of Human l-Opioid and ORL1
Receptors in HEK 293 Cells
HEK 293 cells were grown in minimal essential medium
(Invitrogen) supplemented with 10% fetal bovine serum,
100 units/ml penicillin, and 100 lg/ml streptomycin. Cell
cultures were maintained at 37 C in a humidiﬁed 5% CO2
incubator. The pcDNA4/V5-His C vector containing cDNA
of HA-tagged human MOR or the pCMV-Tag3 vector
containing cDNA of myc-tagged human ORL1 was trans-
fected to HEK 293 cells by lipofection using FuGENE HD
(Roche, Mannheim, Germany). Cell lines stably expressing
HA-tagged MOR and myc-tagged ORL1 were selected by
adding zeocin (0.5 mg/ml) and geneticin (0.5 mg/ml) to
the culture medium, respectively. Surface expression of
HA-tagged human MOR or myc-tagged human ORL1 was
conﬁrmed by measuring agonist-mediated inhibition of
forskolin-induced cAMP accumulation [28].
Receptor Deglycosylation
HEK cells stably expressing MOR or ORL1 were grown to
nearconﬂuencein10 cmdishes.Cellextractswereprepared
by incubating the cells in 0.4 ml of lysis buffer—composed
of 150 mM Tris–HCl (pH 7.4), 300 mM NaCl, 1 mM
MgCl2, 1 mM CaCl2, 1% Triton X-100, 10% glycerol, and
1%proteaseinhibitormixture(containingaprotinin,leupep-
tin, pepstatin A, 4-(2-aminoethyl)benzenesulfonyl ﬂuoride
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MO, USA)—for 1 h on ice. Cell debris was precipitated by
centrifugation at 14 000 g for 10 min at 4 C and the super-
natantwasusedfortheanalysis.Proteinconcentrationofthe
supernatant was determined using the BCA assay (Pierce
Biotechnology, Rockford, IL, USA) with bovine serum
albumin as standard. To investigate receptor glycosylation,
20 lg protein was incubated with 1 unit N-glycosidase F
(Roche) in deglycosylation buffer—consisting of 25 mM
sodium phosphate buffer (pH 7.2), 25 mM EDTA, 0.1%
SDS,and1%(v/v)2-mercaptoethanol—at37 Cfor3 h[33].
For immunoblotting, treated and untreated lysates were
diluted with 69 gel loading buffer (300 mM Tris–Cl (pH
6.8),12%(w/v)SDS,0.3%(w/v)bromophenolblue,60%(v/
v) glycerol, and 600 mM b-mercaptoethanol); and proteins
were resolved using 10% SDS polyacrylamide gel and
then transferred to polyvinylidene diﬂuoride membranes
(Immobilon; Millipore, Billerica, MA, USA). Membranes
were incubated with monoclonal anti-HA or anti-myc anti-
body (1:1000 dilution; Cell Signaling Technology, Danvers,
MA, USA) overnight at 4 C. After being washed, mem-
branes were incubated with sheep anti-mouse horseradish
peroxidase-linked secondary antibody (GE Healthcare Life
Sciences, Piscataway, NJ, USA). Subsequently, immuno-
reactive proteins on the membrane were visualized by
enhanced chemiluminescence (SuperSignal West Pico
chemiluminescent substrate kit; Pierce Biotechnology,
Rockford, IL, USA). Molecular weights were determined
using ImageQuant TL (GE Healthcare Life Sciences).
Radioligand Binding Assays
HEK 293 cells were washed twice and harvested on ice in
Versene solution containing 0.2 g/L EDTA•4Na in phos-
phate-buffered saline (Invitrogen) and centrifuged at
500 g for 3 min at 4 C. The cell pellet was suspended in
buffer A—consisting of 5 mM Tris–Cl (pH 7.4), 5 mM
EDTA, 5 mM EGTA, and 0.1 mM phenylmethylsulfonyl
ﬂuoride—passed through a 26-gauge1/2 needle 5 times,and
thencentrifugedat48000 gfor30 min.Themembranepellet
wasresuspendedusingaPolytronhomogenizerinbufferB—
composed of 50 mM Tris–Cl (pH 7.0) and 0.32 mM
sucrose—aliquoted, frozen in dry ice/ethanol, and stored at
–80 C. Protein concentration of the membrane preparation
was measured by the Bradford method (Bio-Rad protein
assay kit, Bio-Rad Laboratories, Hercules, CA, USA).
Saturation radioligand binding assay was performed
using opaque white 96-well ﬁlter plates with FB glass ﬁber
ﬁlters (model MSFB N6B, Multiscreen Assay System;
Millipore). Cell membranes (8 * 12 and 50 lg of protein/
well for nociceptin and DAMGO binding, respectively)
were incubated with various concentrations of [
3H]-noci-
ceptin (PerkinElmer Life Analytical Sciences, Boston, MA,
USA) or [
3H]-DAMGO (PerkinElmer) in binding buffer
consisting of 50 mM Tris–Cl (pH 7.4) and 1 mM EGTA
for 1 h at 25 C. Non-speciﬁc binding was determined by
adding 3 lM nociceptin (Tocris Bioscience, Ellisville,
Missouri, USA) or DAMGO (Tocris) to the reaction mix-
ture. The reaction was terminated by rapid ﬁltration, and
the ﬁlters were washed 3 times with ice-cold binding
buffer and dried at room temperature, overnight. After
adding MicroScint-20 cocktail (PerkinElmer), bound
radioactivity was measured using the TopCount NXT
microplate scintillation and luminescence counter (Perkin-
Elmer). Prism (GraphPad Software, La Jolla, CA, USA)
was used to analyze the data derived from the saturation
binding assay to obtain Bmax and KD values.
Confocal Microscopy and Image Analysis
Cells were grown on microscope cover glasses (Fisher
Scientiﬁc, Pittsburgh, PA, USA) and incubated for
2–3 days prior to immunocytochemistry. Immunostain-
ing was performed by incubating the cells at 37 C with
1:100 dilution of monoclonal anti-HA (Cell Signaling
Technology) or polyclonal anti-ORL1 (raised against
the N-terminus of the human OPRL1 receptor,
MEPLFPAPFWEVIYGSHL, and afﬁnity-puriﬁed by Pro-
Sci Incorporated, Poway, CA, USA) antibody in complete
medium for 1.5 h. After three washes in complete medium
and two washes in PBS
? (1 9 phosphate-buffered saline
containing 1 mM MgCl2 and 0.1 mM CaCl2), cells were
ﬁxed with 4% paraformaldehyde at room temperature for
15 min. After quenching with two washes with 50 mM
NH4Cl in PBS
? and washed once with PBS
?, cells were
permeabilized with 0.1% Triton X-100 in PBS
? at room
temperature for 15 min. To remove excess Triton X-100,
cells were washed 5 times with PBS
? at room temperature.
Nonspeciﬁc binding was then blocked by incubating the
cells with 10% BSA in PBS
? at room temperature for
30 min. The secondary antibody (1:500 dilution of Alexa
Fluor 488 goat anti-mouse or Alexa Fluor 647 anti-rabbit
antibody, Invitrogen) was applied at 4 C overnight. Cells
were then washed 3 times with PBS
? and mounted (Pro-
Long Gold Antifade Kit, Invitrogen) for imaging. Images
were acquired using a Leica TCS SP5 confocal microscope
(Leica Microsystems CMS GmbH, Mannheim, Germany)
with a 63 9 1.4 NA oil immersion objective in the inverted
conﬁguration. Quantitative analysis of colocalization rate
was performed using Leica LAS-AF software based on
30% background subtractions in both receptors and 30%
threshold for determining colocalization.
2010 Neurochem Res (2011) 36:2008–2021
123HTRF cAMP Assays
The cAMP quantiﬁcation was performed using a homoge-
neoustime-resolvedﬂuorescence(HTRF)cAMPdetectionkit
(cAMPHiRange;Cisbio,Bagnols/Ce `zeCedex,France).HEK
293 cells were dispensed with 25 llo fc o m p o u n db u f f e r
consisted of minimal essential medium supplemented with
0.5 mMisobutylmethylxanthine(Sigma–Aldrich),0.2%fatty
acid-free bovineserum albumin (Sigma–Aldrich),0.5 mg/ml
zeocin,and/or0.5 mg/mlgeneticinat2–6 9 10
4cells/wellin
96half-well plates(Costar,Corning, NY, USA)onthe day of
the experiment. After an incubation of 1 h at 37 Ci na
humidiﬁed 5% CO2 incubator, 25 ll of compound buffer
containing 10 lM forskolin and desired concentrations of
methadone (United States Pharmacopeia, Rockville, MD,
USA) or buprenorphine (Sigma–Aldrich) were added to the
cells, followed by 30 min incubation at room temperature.
Morphine (National Bureau of Controlled Drugs, Taipei,
Taiwan) and Ro 64-6198 (a gift from F. Hoffmann-La Roche
Ltd., Basel, Switzerland)—which are a MOR agonist and an
ORL1 agonist, respectively—were included as the positive
control. Subsequently, 25 ll of cAMP-d2 and 25 llo fa n t i -
cAMP Cryptateconjugate were added to each well. After 1 h
incubation at room temperature, the plate was read on a
FlexStation 3 microplate reader (Molecular Devices, Silicon
Valley, CA, USA) with emission wavelength at 615 and
665 nm.
To verify the speciﬁcity of the drugs, 1 lM naloxone
(Sigma–Aldrich) was included in the compound buffer
containing 10 lM forskolin and 0.1 lM opioids, followed
by 30 min co-incubation at room temperature. For evalu-
ation of AC superactivation, desired concentrations of
drugs were added to the compound buffer and incubated at
37 C for 30 min or 4 h; the compound buffer was then
replaced by either 10 lM forskolin only or in combination
with 1 lM naloxone. Afterward, the incubation with
cAMP-d2 and anti-cAMP Cryptate conjugate was imme-
diately carried out as stated above. The cAMP concentra-
tions were calculated by nonlinear regression analysis with
SoftMax Pro (Molecular Devices, Sunnyvale, CA, USA).
Concentration-response curves of cAMP accumulation,
potency (pIC50) and efﬁcacy (Emax) for inhibition of for-
skolin-stimulated cAMP formation by morphine, metha-
done, buprenorphine, and Ro 64-6198 were analyzed using
Prism (GraphPad Software) [34, 35].
Statistical Analyses
All results are expressed as the mean ± SE value of
n experiments. Paired/unpaired t test (two-tailed) or one-
way/two-way ANOVA followed by Bonferroni’s test was
used to determine whether the difference is statistically
signiﬁcant (P\0.05).
Results
Establishment of HEK 293 Cells Stably Expressing
HA-Tagged MOR and Myc-Tagged ORL1
We have established an in vitro cell model by over-
expressing epitope-tagged human MOR and ORL1 in HEK
293 cells. Plasmids harboring HA-tagged MOR or myc-
tagged ORL1 were individually or simultaneously trans-
fected in HEK 293 cells, and the stable clones were selected
by appropriate antibiotics. Since adenylate cyclase (AC)
activity is the major endpoint measured in this study, the
three stable clones presented here (MOR-, ORL1-, and
MOR?ORL1-expressing cells) were chosen based on the
strongest adenylate AC inhibition by acute treatment of
1 lM of DAMGO and/or nociceptin compared to other
stable clones during the initial screening. Subsequent
experiments also demonstrated similar AC inhibition levels
between the MOR- and MOR?ORL1-expressing cells or
those between the ORL1- and MOR?ORL1-expressing
cells elicited by MOR or ORL1 agonists (Fig. 3 and
Table 2). Western blot analysis using monoclonal anti-HA
antibody revealed that MOR was expressed as two major
heterogeneous forms, with apparent molecular masses
of *43–50 and 72–80 kilodaltons (kDa) (Fig. 1, Left
panel). Due to its smaller mass, the ORL1 revealed by anti-
myc antibody migrated more quickly as two major diffused
bands with apparent molecular masses of *46–50 and
67–75 kDa. The minor band at *55 kDa is supposedly a
non-speciﬁc protein elicited by overexpression of the plas-
midharboringthemyc-ORL1receptor(Fig. 1,Rightpanel).
Since the apparent molecular weights of the overex-
pressed MOR and ORL1 were larger than the expected
values, we hypothesized that the overexpressed human
MOR and ORL1 might undergo glycosylation [2]. Evi-
dence that MOR and ORL1 are glycoproteins was provided
by digestion with N-glycosidase F, an amidase that cleaves
nearly all types of N-glycan chains from the asparagines in
N-linked glycoproteins. N-Glycosidase F treatment of
MOR and ORL1 increased the mobility of both bands to
species of apparent molecular masses of 43 kDa for MOR,
and 39 and 41 kDa for ORL1. The predicted molecular
masses for the HA-tagged MOR and myc-tagged ORL1
are *45 and 43 kDa, respectively. The reason for the
aberrant electrophoretic mobility of the receptors, even
after deglycosylation, is unknown at present [33]. The
immunoreactive bands with slower mobility may represent
opioid receptor dimers described previously [3, 36].
In saturation radioligand binding studies, [
3H]-DAMGO
displayed a similar afﬁnity (KD) for both stably transfected
celllinesharboringMOR;butcellsexpressingMOR?ORL1
possess more DAMGO-binding sites than those expressing
MOR alone, as reﬂected by the signiﬁcantly higher Bmax
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3H]-nociceptin showed sig-
niﬁcantly higher afﬁnity (lower KD value) for cells
expressingbothMORandORL1thancellsexpressingORL1
alone;yetcellsco-expressingMORandORL1possessfewer
nociceptin-binding sites than those expressing only ORL1,
as demonstrated by the lower Bmax value (Table 1).
We next examined whether MOR colocalizes with
coexpressed ORL1. Shown in Fig. 2 are confocal ﬂuores-
cence images of HEK 293 cells expressing HA-tagged
MOR and myc-tagged ORL1. ORL1 was clearly present in
vesicles distributed throughout the cytoplasm and also on
the plasma membrane. MOR localizes to the cell surface as
well as vesicular structures, and prominently colocalizes
with ORL1 (colocalization rate: 83.65 ± 4.33%).
AC Inhibition After Acute Opioid Exposure
Methadone Inhibited AC as a MOR Agonist
Effects of acute exposure to morphine, methadone, bupr-
enorphine, and Ro 64-6198 on MOR- or ORL1-mediated
Gai/o-coupled adenylate cyclase (AC) inhibition were
examined. Morphine and methadone concentration-depen-
dently inhibited forskolin-stimulated cAMP accumulation
in HEK 293cells expressingMOR only (Fig. 3a and b, open
circles; Table 2) as well as MOR?ORL1 (Fig. 3a and b,
ﬁlled squares; Table 2). Methadone was somewhat more
potent than morphine in cells expressing only MOR
(Table 2a) (pIC50: 7.526 ± 0.127 vs. 6.702 ± 0.276) or
MOR?ORL1 (Table 2b) (pIC50: 7.294 ± 0.150 vs.
7.024 ± 0.193), although the difference is not statistically
signiﬁcant. In HEK 293 cells stably expressing ORL1,
morphine and methadone did not inhibit forskolin-stimu-
lated AC activity (Fig. 3a and b, open triangles). These
results suggest that methadone acts as a potent MORagonist
comparable to morphine and has no effect on ORL1.
Buprenorphine Acted as an ORL1 Agonist and a Partial
MOR Agonist
Unlike methadone, buprenorphine displayed a ﬂat con-
centration-inhibition curve on cAMP accumulation in
Fig. 1 MOR and ORL1 expressed in HEK 293 cells are N-linked
glycoproteins. Cell lysates were prepared by extracting monolayers of
HEK 293 cells expressing HA-tagged MOR and/or myc-tagged ORL1
receptors in lysis buffer for 1 h on ice. Cellular debris was pelleted by
centrifugation; and the supernatants were treated with or without
N-glycosidase F (protease-free, 50 units/mg of membrane protein) at
37 C for 3 h, then resolved using 10% SDS-PAGE. HA- or myc-
tagged receptors were assayed by immunoblotting using the mono-
clonal anti-HA (Left panel) or anti-myc (Right panel) antibody. The
mobilities of molecular mass standards (in kDa) are indicated to the
left. -, glycosylated (untreated) receptors; ?, deglycosylated (treated
with N-glycosidase F) receptors





Bmax (pmol/mg protein) KD (nM) Bmax (pmol/mg protein) KD (nM)
MOR 0.67 ± 0.07 5.25 ± 0.54
ORL1 109.34 ± 54.11 2.83 ± 0.80
MOR?ORL1 1.09 ± 0.14
# 5.85 ± 0.72 17.38 ± 6.01 0.69 ± 0.20
*
Saturation binding assays were performed with [
3H]-DAMGO or [
3H]-nociceptin. Each value represents the mean ± SE of four to ﬁve
experiments performed in duplicate
# indicates the signiﬁcant difference (P\0.05) between Bmax values of cells expressing only MOR and both MOR and ORL1
* indicates the signiﬁcant difference (P\0.05) between KD values of ORL1-expressing cells and MOR?ORL1-expressing cells, according
to unpaired t test (two-tailed) analysis
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inhibition (Fig. 3c, open circles; Table 2), supporting its
partial agonist characteristic at MOR. In ORL1-expressing
cells, buprenorphine at higher concentrations ([30 nM)
inhibited cAMP accumulation in a concentration-dependent
manner(Fig. 3c,opentriangles;Table 2),asdidRo64-6198
(Fig. 3d, open triangles; Table 2), a non-peptide ORL1
agonist [37]. This suggests that buprenorphine acts as an
ORL1 agonist at higher concentrations. Interestingly, bupr-
enorphine showed a signiﬁcantly greater potency (higher
pIC50)(Table 2c)butlowerefﬁcacy(lowerEmax)(Table 2d)
in MOR?ORL1-coexpressing cells than in cells expressing
ORL1 only (Fig. 3c; Table 2). However, the AC inhibition
curves elicited by Ro 64-6198 were comparable in ORL1-
and MOR?ORL1-expressing cells (Fig. 3d; Table 2). This
suggests that the effect of buprenorphine on MOR?ORL1-
expressing cells is not solely owing to its agonistic property
on ORL1 receptor.
Interactions of Naloxone
Naloxone, a generic opioid receptor antagonist, was
co-incubated with 0.1 lM morphine, methadone and bupr-
enorphine to verify if their effects were mediated by MOR.
At 1 lM, naloxone did not affect forskolin-stimulated
cAMP accumulation per se (nalox). However, it com-
pletely reversed the inhibitory effects of morphine and
methadone; but it only slightly reversed the inhibitory
effect of buprenorphine in cells expressing MOR (Fig. 4a)
and MOR?ORL1 (Fig. 4b). Additionally, naloxone did not
affect the Ro 64-6198-induced inhibition on cAMP accu-
mulation (Fig. 4b and c), suggesting that naloxone at 1 lM
speciﬁcally targets MOR and leaves ORL1 unaffected.
Naloxone, if added at the end of 30 min opioid exposure,
relieved AC inhibition by morphine in cells expressing MOR
orMOR?ORL1andevencausedareboundfacilitationofAC
activity in the lM range (Fig. 5a). In cells treated with
methadone, the AC activity was changed in a proﬁle remi-
niscentofthoseexposedtomorphineafternaloxonechallenge
(Fig. 5b). Naloxone completely relieved buprenorphine-
inducedACinhibitionbutdidnotinducereboundACactivity
in cells expressing MOR and MOR?ORL1 (Fig. 5c). Inter-
estingly, naloxone also signiﬁcantly relieved the AC inhibi-
tion induced by buprenorphine at higher concentrations
(Fig. 5c) as well as that induced by Ro 64-6198 (Fig. 5d) in
ORL1-expressing cells. These results demonstrate that nal-
oxone relieved AC inhibition induced by MOR agonists
(morphine,methadone,andbuprenorphine)andeveninduced
rebound AC activity after 30 min exposure to higher con-
centrations of MOR agonists (morphine and methadone) but
notaftersimilarexposuretoapartialagonist(buprenorphine).
NaloxonealsopartiallyrelievedtheACinhibitioninducedby
ORL1 agonists, buprenorphine (Fig. 5c) and Ro 64-6198
(Fig. 5d), at higher concentrations in ORL1-expressing cells.
Fig. 2 Representative confocal images from cells expressing MOR
(Upper left panel), ORL1 (Upper right panel), and MOR?ORL1
(Lower panels). HA-tagged MOR was detected with anti-HA mouse
monoclonal antibody and visualized by Alexa Fluor 488 goat anti-
mouse antibody (green); myc-tagged ORL1 was detected with anti-
ORL1 rabbit polyclonal antibody and visualized by Alexa Fluor 647
goat anti-rabbit antibody (red); the colocalization of MOR and ORL1
is depicted in yellow in the merged picture. Scale bars are equal to
10 lm
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enorphine, or Ro 64-6198 on forskolin-stimulated cAMP accumula-
tion in HEK 293 cells expressing MOR and/or ORL1. HEK 293 cells
expressing MOR (open circle), ORL1 (open triangle) or both MOR
and ORL1 (ﬁlled square) were treated with morphine (a), methadone
(b), buprenorphine (c), or Ro 64-6198 (d) for 30 min at room
temperature in the presence of 10 lM forskolin prior to HTRF cAMP
assays. Each point represents the mean ± SE value of four experi-
ments performed in duplicate using different batches of cells. 100%
deﬁnes forskolin-stimulated cAMP accumulation in cells not treated
with aforementioned drugs. Asterisks in (c) indicate the very
signiﬁcant difference (P\0.01) between curves of ORL1-expressing
cells and MOR?ORL1-expressing cells according to paired t test
(two-tailed) analysis
Table 2 Potency (pIC50) and efﬁcacy (Emax) for inhibition of forskolin-stimulated cAMP formation by morphine, methadone, buprenorphine,
and Ro 64-6198 in HEK 293 cells expressing l-opioid receptors (MOR) and opioid receptor-like 1 receptors (ORL1)
Drug Receptor(s) pIC50 Emax (% inhibition)
Morphine MOR 6.702 ± 0.276
a 75.44 ± 13.97
MOR?ORL1 7.024 ± 0.193
b 77.54 ± 9.03
ORL1 N/C N/C
Methadone MOR 7.526 ± 0.127
a 76.79 ± 3.99
MOR?ORL1 7.294 ± 0.150
b 85.89 ± 6.24
ORL1 N/C N/C
Buprenorphine MOR 8.224 ± 0.645 33.52 ± 3.38
MOR?ORL1 7.412 ± 0.227*
c 50.84 ± 4.37
d
ORL1 6.346 ± 0.214*
c 90.51 ± 18.66
d
Ro 64-6198 MOR N/C N/C
MOR?ORL1 8.465 ± 0.270 87.10 ± 5.16
ORL1 8.746 ± 0.422 84.27 ± 6.67
Values represent the mean ± SE of four experiments performed in duplicate as described in Fig. 3
* indicates a signiﬁcant difference (P\0.05) between the pIC50 value of ORL1-expressing cells and that of MOR?ORL1-expressing cells,
according to two-way ANOVA with Bonferroni correction. N/C = not converged. Lowercase letters (a–d) denote the points of comparisons
described in the text
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AC Superactivation After Naloxone Challenge Following
Long-Term Opioid Exposure
The above results show that rebound AC activity can be
induced by naloxone in cells exposed to MOR agonists for
only 30 min. Accordingly, we extended our investigation
by adding naloxone to cells exposed to opioids for 4 h, an
incubation period reported to show a prominent overshoot
in forskolin-stimulated cAMP accumulation [38].
When HEK 293 cells expressing MOR and MOR?
ORL1 were exposed to morphine or methadone for 4 h,
addition of naloxone caused AC superactivation, as
revealed by the overshoot (up to 400%) of cAMP accu-
mulation (Fig. 6a and b). However, no AC superactivation
was observed in MOR-expressing cells chronically
exposed to buprenorphine (Fig. 6c) or Ro 64-6198 (except
at[0.3 lM) (Fig. 6d) after naloxone challenge. Interest-
ingly, AC superactivation did occur in ORL1- and
MOR?ORL1-expressing cells chronically exposed to
buprenorphine, and ORL1-expressing cells even exhibited
larger magnitude of AC superactivation than MOR?
ORL1-expressing cells, as shown in the higher slope value
in linear regression analysis (Fig. 6c). Chronic treatment
with Ro 64-6198 also responded to naloxone ‘‘precipita-
tion’’ and resulted in AC superactivation in cells expressing
ORL1, both individually and simultaneously, with
intriguingly bell-shaped concentration-response curves and
higher efﬁcacy in cells coexpressing MOR and ORL1
(Fig. 6d).
AC Superactivation After Agonist Removal Following
Long-Term Opioid Exposure
Since naloxone does not act on ORL1 (Fig. 4) yet cells
stably expressing ORL1 showed AC superactivation upon
addition of naloxone (Fig. 6c and d), we investigated
whether removal of agonist is sufﬁcient to reveal AC
superactivation after prolonged agonist exposure. Indeed,
both buprenorphine and Ro 64-6198 resulted in AC
superactivation (sixfold and 2.5-fold increases for bupr-
enorphine and Ro 64-6198, respectively) after agonist
removal in cells expressing solely ORL1 (Fig. 7c and d).
Not surprisingly, morphine and methadone were still able
to stimulate AC superactivation, yet to a lesser extent, in
cells expressing MOR and MOR?ORL1 in the absence of
naloxone challenge (Fig. 7a and b). Hence, we demon-
strated that ‘‘natural withdrawal’’ by washout (Fig. 7) and
‘‘precipitated withdrawal’’ by naloxone (Fig. 6) have
similar effects on cAMP accumulation; additionally,
chronic exposure to buprenorphine and Ro 64-6198 could
also contribute to the ‘‘withdrawal syndrome’’ (i.e. AC
Fig. 4 Blockade by naloxone of the morphine, methadone, and
buprenorphine inhibition on forskolin-stimulated cAMP accumulation
in HEK 293 cells expressing MOR and/or ORL1. HEK 293 cells
expressing MOR (a), MOR?ORL1 (b), or ORL1 (c) were treated
with 0.1 lM morphine (morph), methadone (methad), buprenorphine
(bupren), or Ro 64-6198 (Ro) in the presence or absence of 1 lM
naloxone (nalox) for 30 min at room temperature with 10 lM
forskolin prior to HTRF cAMP assays. Each point represents the
mean ± SE value of four experiments performed in duplicate using
different batches of cells. 100% deﬁnes forskolin-stimulated cAMP
accumulation in cells not treated with aforementioned drugs. The
signiﬁcance of differences between without and with naloxone
treatment were determined by one-way ANOVA followed by
Bonferroni’s test, *P\0.05, ***P\0.001
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Heterodimerization has been reported for MOR and various
receptors, such as the d opioid receptor [39], ORL1 receptor
[28], sst2A somatostatin receptor [40], substance P receptor
[41], cannabinoid CB1 receptor [42], and metabotropic glu-
tamate receptor 5 [43]. Receptor heterodimerization usually
leadstoalterationsinMORphosphorylation,internalization,
desensitization, MAPK activation, and coupling to voltage-
dependent Ca
2? channels [44]. We demonstrated the colo-
calization of coexpressed human MOR and ORL1 receptors
in HEK 293 cells (Fig. 2). Although the colocalization rate
did not reach 100%, indicating the presence of homomers in
the coexpressed condition, the high colocalization rate
suggests the formation of heterodimerized MOR-ORL1 as
recently reported in tsA-201 cell [29]. We attempted to
co-immunoprecipitate the coexpressed human MOR and
ORL1 using anti-HA and anti-myc antibodies, but were
unable todetect the direct associationof MOR andORL1 by
pulling down the receptors together. Hence, human MOR
and ORL1 may indeed heterodimerize but cannot be
co-immunoprecipitated,orco-immunoprecipitationwiththe
anti-N-terminal epitope tags is unable to detect the associa-
tionofhumanMORandORL1.Oursaturationbindingassay
using [
3H]-nociceptin (Table 1)—which showed that
co-expressing ORL1 with MOR reduced the number of
nociceptin-binding sites (lower Bmax) yet signiﬁcantly
increasedthenociceptinafﬁnityofthereceptor(lowerKD)—
also implies the novel properties of coexpressed human
MOR-ORL1 receptors. This interesting phenomenon was
notseeninHEK293cellsco-expressingratMORandORL1
[28]. Since the expression levels of myc-tagged ORL1 are
not drastically different in cells expressing ORL1 alone and
MOR?ORL1 as revealed by immunoblotting (Fig. 1), the
reduction of Bmax might be due to the decreased number of
ORL1 transported from ER-Golgi to the plasma membrane
[45]. Another possibility is that coexpressed human MOR
and ORL1, perhaps forming heteromers, adopted a different
Fig. 5 Effects of naloxone on acute exposures to morphine, meth-
adone, buprenorphine, or Ro 64-6198 on forskolin-induced cAMP
accumulation in HEK 293 cells expressing MOR and/or ORL1. After
exposure to morphine (a), methadone (b), buprenorphine (c), or Ro
64-6198 (d) for 30 min at room temperature, the incubation media
were subsequently removed, and HEK 293 cells expressing MOR
(open circle), ORL1 (open triangle) or both MOR and ORL1 (ﬁlled
square) were treated with 1 lM naloxone accompanied by 10 lM
forskolin immediately prior to HTRF cAMP assays. Each point
represents the mean ± SE value of four experiments performed in
duplicate using different batches of cells. 100% deﬁnes forskolin-
stimulated cAMP accumulation in cells treated with none of the
aforementioned drugs but naloxone. Asterisks indicate the signiﬁcant
differences (**P\0.01, ***P\0.001) between curves of MOR-
expressing cells and MOR?ORL1-expressing cells according to
paired t test (two-tailed) analysis
2016 Neurochem Res (2011) 36:2008–2021
123conformation of the nociceptin-binding site from ORL1,
rendering the binding afﬁnity higher than ORL1 homomers
[43, 46]. A potential caveat of the overexpression system is
that the interaction between two overexpressed receptors
might be mass action-induced and does not exist in endog-
enous system where the receptor abundance is much lower.
Therefore, our in vitro cell model is a simpliﬁed system to
address the possible heterodimerization between MOR and
ORL1, and may not truthfully reﬂect the native condition of
these two opioid receptors in the in vivo system.
Acute activation of MOR and ORL1 Inhibits AC
Activity
Acute agonist exposure inhibits forskolin-induced accu-
mulation of cAMP in recombinant HEK 293 cells
expressing cloned MOR [47] or ORL1 [48]; this effect is
mediated by inhibition of AC activity upon opioid receptor
activation [49, 50]. In our cell model, acute treatment with
two MOR agonists, morphine and methadone, speciﬁcally
repressed the AC activity in cells expressing recombinant
MOR. The ORL1 agonist, Ro 64-6198, acutely inhibited
AC in cells expressing recombinant ORL1 but not MOR
alone. Buprenorphine, which acted as a partial agonist at
MOR and as a full agonist at ORL1, exhibited an inter-
mediate potency (pIC50) and efﬁcacy (Emax) in cells
coexpressing MOR and ORL1 in comparison to MOR or
ORL1 alone (Table 2). This intermediate response might
result from the heterodimerization of MOR and ORL1, or
the simultaneous regulation of common secondary mes-
sengers by MOR and ORL1.
Changes in the cAMP system in the locus coeruleus
(LC) play a role in mediating acute opioid action and
underlying the development of opioid dependence and
withdrawal [51]. Morphine acutely inhibited AC in vitro in
the LC, dorsal raphe, frontal cortex, and neostriatum; and
the inhibition was blocked by naloxone. This response is
mediated by a pertussis toxin-sensitive G-protein (i.e. Gi/o)
[51]. We successfully replicated the phenomenon in the in
Fig. 6 Naloxone precipitation on the effects of chronic exposures to
morphine, methadone, buprenorphine, or Ro 64-6198 on forskolin-
stimulated cAMP accumulation in HEK 293 cells expressing MOR
and/or ORL1. HEK 293 cells expressing MOR (open circle), ORL1
(open triangle) or both MOR and ORL1 (ﬁlled square) were treated
with morphine (a), methadone (b), buprenorphine (c), or Ro 64-6198
(d) for 4 h at 37 C. The incubation medium was subsequently
replaced by 1 lM naloxone and 10 lM forskolin in compound buffer
prior to HTRF cAMP assays. Each point represents the mean ± SE
value of four experiments performed in duplicate using different
batches of cells. 100% deﬁnes forskolin-stimulated cAMP accumu-
lation in cells not treated with aforementioned drugs. Asterisks
indicate the extremely signiﬁcant differences (P\0.001) between
curves of cells expressing MOR alone (open circle) and both MOR
and ORL1 (ﬁlled square). Pound signs indicate the extremely
signiﬁcant difference (P\0.001) between curves of cells expressing
only ORL1 (open triangle) and both MOR and ORL1 (ﬁlled square)
according to paired t test (two-tailed) analysis. Dashed and dotted
lines represents the linear regression ﬁtted to the 6 data points at the
high concentration end of cells expressing ORL1 (open triangle;
slope = 186.4 ± 30.82) and both MOR and ORL1 (ﬁlled square;
slope = 97.80 ± 17.31), respectively. Arrows indicate the signiﬁcant
difference (P\0.05) between the slopes of the linear regression
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123vitro cell model: morphine acutely inhibited AC in HEK
293 cells overexpressing MOR and MOR?ORL1
(Fig. 3a); and the inhibition was also blocked by naloxone
(Fig. 3a and b). Acute exposure to agonists of Gi/o-coupled
receptors—such as MOR, m4 (muscarinic type 4), D2
(dopaminergic type 2), and CB1 (cannabinoid type 1)
receptors—inhibits the activity of AC types I, V, VI, and
VIII, while stimulating the activity of AC types II, IV, and
VII [25, 52]. Furthermore, acute activation of Gi/o-coupled
receptors leads to inhibition of AC-VIII-A and -B, but not
of the AC-VIII-C splice variant in COS-7 cells transfected
with MOR [53]. It would be interesting to investigate
whether the cells coexpressing MOR and ORL1 utilize the
same mechanism to regulate AC activity as well.
AC Superactivation After Chronic Agonist Treatment
Opioid-induced AC superactivation has been widely used
as an indicator of cellular dependence [54]. Cell lines
expressing either MOR or ORL1 have been successfully
utilized to investigate the overshoot of AC activity
following chronic treatment of agonists [38, 55]. The
present study further used cells co-expressing MOR and
ORL1 and observed unique responses of the coexpressed
MOR?ORL1 receptors, which suggests that coexpressed
MOR?ORL1 receptors perhaps represent a distinct popu-
lation of the opioid receptors: ones that bear pharmaco-
logical proﬁles different from either MOR or ORL1 alone.
Our results demonstrated that the AC superactivation could
start as early as 30 min after morphine or methadone
treatment (Fig. 5a and b); and 4 h incubation with the
MOR agonist resulted in profound AC superactivation
either in the presence of naloxone challenge (Fig. 6)o r
simply after agonist washout (Fig. 7).
The LC nucleus possesses a high density of opioid
receptors, particularly MOR [56] and ORL1 [57]. Chronic
morphine administration elevates levels of AC-I and
AC-VIII in the LC [58] and knockout of either calmodulin-
dependent isoform attenuates the ability of chronic mor-
phine exposure to increase LC neuronal excitability and
behavioral features of opioid withdrawal [59]. Blockade of
cAMP response-element binding protein (CREB) in the LC
Fig. 7 ‘‘Natural withdrawal’’ on the effects of chronic exposures to
morphine, methadone, buprenorphine, or Ro 64-6198 on forskolin-
stimulated cAMP accumulation in HEK 293 cells expressing ORL1
and/or MOR. HEK 293 cells expressing MOR (open circle), ORL1
(open triangle) or both MOR and ORL1 (ﬁlled square) were treated
with morphine (a), methadone (b), buprenorphine (c), or Ro 64-6198
(d) for 4 h at 37 C. The incubation medium was subsequently
replaced by 10 lM forskolin in compound buffer prior to HTRF
cAMP assays. Each point represents the mean ± SE value of four
experiments performed in duplicate using different batches of cells.
100% deﬁnes forskolin-stimulated cAMP accumulation in cells not
treated with aforementioned drugs. Dashed and dotted lines repre-
sents the linear regression ﬁtted to the six data points at the high
concentration end of cells expressing ORL1 (open triangle;
slope = 235.8 ± 32.62) and both MOR and ORL1 (ﬁlled square;
slope = 101.9 ± 13.89), respectively. Arrows indicate the extremely
signiﬁcant difference ( P\0.001) between the slopes of the linear
regression. Pound signs indicate the signiﬁcant difference (P\0.05)
between curves of cells expressing only ORL1 (open triangle) and
both MOR and ORL1 (ﬁlled square) according to paired t test (two-
tailed) analysis
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123prevents the opioid-induced AC-VIII up-regulation [58].
Such blockade also diminishes the ability of chronic mor-
phine treatment to increase LC neuronal excitability and to
induce dependence and withdrawal [58, 60]. An ex vivo
LC slice culture system combined with viral-mediated gene
transfer and genetic mutant mice provides direct evidence
supporting that prolonged morphine exposure induces
homeostatic adaptations intrinsic to LC neurons, involving
up-regulation of cAMP-CREB pathway, which enhances
LC neuronal excitability [61]. Given the colocalization of
MOR and ORL1 in the LC and our HEK 293 cells (Fig. 2),
the present in vitro cell model expressing MOR?ORL1
offers the opportunity to dissect, in a simpliﬁed and
more accessible manner, the relationship among MOR,
ORL1, AC-I, AC-VIII, cAMP-CREB, and cell excitability
during chronic exposure to morphine, methadone, and
buprenorphine.
AC Superactivation Induced by Buprenorphine and Ro
64-6198 at ORL1
Although buprenorphine did not elicit AC superactivation
at the 30 min time point (Fig. 5c), 4 h buprenorphine
exposure induced prominent forskolin-induced cAMP
accumulation (*3.5 fold) in MOR?ORL1-expressing
cells and drastically high cAMP accumulation (*sixfold)
in ORL1-expressing cells (Figs. 6c and 7c). Another
striking observation is the bell-shaped curve of Ro
64-6198-induced AC superactivation (Figs. 6d and 7d).
This biphasic response might reﬂect an intrinsic ORL1
property that receptor activation by higher concentration
(above 0.1 lM) of agonists would generate a reduction, not
an enhancement, of AC superactivation, thus contributing
to its role in modulating opioid antinociception [62] and
blocking the rewarding effects of several abused drugs,
including morphine [63], cocaine [64], and amphetamine
[65]. The difference between buprenorphine and Ro
64-6198 remains to be elucidated if it is due to the dif-
ference between the partial agonist (buprenorphine) and
full agonist (Ro 64-6198) for ORL1.
Clinical Implications
When the responses to long-term treatment of methadone
and buprenorphine are compared, cells expressing both
MOR and ORL1 display matching concentration-response
curves (Fig. 6b and c; Fig. 7b and c, ﬁlled squares). In
contrast, cells expressing MOR alone concentration-
dependently responded to methadone, not to buprenor-
phine (Fig. 6b and c; Fig. 7b and c, open circles), whereas
ORL1-expressing cells exhibited concentration-dependent
response to buprenorphine but not to methadone (Fig. 6b
and c; Fig. 7b and c, open triangles). This implies that
chronic methadone and buprenorphine treatments induce
differential effects on cells expressing either MOR or
ORL1 alone, yet lead to similar cellular responses in the
context of coexpressed MOR and ORL1. Therefore, our
cellular model could mimic the physiological responses of
patients, expressing both MOR and ORL1, under mainte-
nance therapy.
The temporal difference between spontaneous and pre-
cipitated withdrawal might be explained by our cell model,
revealing that naloxone-precipitated withdrawal (Fig. 6)
elicited more prominent AC superactivation than natural
withdrawal (Fig. 7) after chronic opioid exposure. More-
over, naloxone produces ‘‘overshoot’’ phenomena sugges-
tive of early acute physical dependence 6–24 h after a
single dose of a MOR agonist [66]. This acute physical
dependence is reﬂected in the elevated AC activity pre-
cipitated by naloxone in MOR-expressing cells after
30 min exposure to morphine and methadone (Fig. 5a and
b). Thus, our study provides a clue to the cellular mecha-
nism of the opioid withdrawal precipitated by naloxone.
In summary, our study suggests that methadone and
buprenorphine exert different adaptive changes on the
secondary messengers. While methadone and morphine
bear almost indistinguishable pharmacological proﬁles in
AC superactivation after chronic treatment, buprenorphine
carries a dissimilar pharmacological portrait, presumably
originating from its agonistic function to ORL1. The in
vitro cell model of coexpressed human MOR?ORL1
receptors provides insight into cross-talk between opioid
receptors following prolonged opioid exposure, and could
provide a new approach to examining novel drugs prior to
their clinical use and an uncomplicated tool for investi-
gating related signaling pathways of opioids at the cellular
level.
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